Mark. of Thanks, Mark's to want A I reiterate section. things couple from
industry. you'll So new us is really for that to service is count the pretty range infrastructure biotech giving a for revenues new broad reason program see guidance. this services our The and
little a bit So blazing opinion. we're here. adds And more a my trail that new bit of in a unpredictability
to at Pfizer, and research biotechnology small for And companies outsourced Boehringer that what large, a to it's in-house today research It's things development big services of are is drive that's -- the doing to with deals Mark providers R&D infrastructure that budgets industry. from cloud infrastructure over by going revenues important. to doing are and decision-makers alternative experience tools in our years. like product infrastructure as in the next biopharma They're Merck, The in these sort in-house so the get those those mentioned really in-house. premises. Ginkgo's how current is core Nordisk, revenue changes an Ginkgo relative getting rate companies. the why outsourcing switch chance others Novo with that first done these for make on of done will to it to service be services And couple reality
commercial driving sales. in -- have less XX-person scale team But we a and unpredictability That's that can the It's fundamentally we I'm as have into of sales we at can what what about factor, do confident big there's really it. they new biopharma. now, question turn into And scale focus to that rate a we a knob? it's
into backs our it. putting we're So
biopharma infrastructure is in Ginkgo dig to What use leaders those what the really that outsourced will to going this that that Why we X are question that. strategic is interested? the parts to Now big my are folks rate happen? first of up for new I'm doing review coming services? on adopt, make
billion Bingo enough Engineering the section, lab and And in of variety Cell biotechnology. invested of products. so critical foundry flexible work first for this to is the across is to for And needed close in in range handle and automation, our has generation that particular, applying, call large-scale wide software $X AI biotech needed that's a for
is all is going want biotech. our I'm services dig section And boats robust see in tide we industry second that grow in view in rising industry, a a infrastructure to the will lift including The on to Ginkgo.
I'll make working to our section talk automation, the about companies. to available service So foundry, first our we're other
the our business industry. need don't in they they doing the build to investments this So repeat as
our recently of relationship Finally, with government we'll give an update the on we Biosecurity, Qatar. strong where expanded
Okay.
in. dive Let's
Okay.
you chart, this tech the world I of of company the So boxes, like the services on underneath can example, the infrastructure you right? of companies the I of even magical industry, what on each on top all of trillion-dollar top okay, often entirely other say side a so left building infrastructure like mean on it. infrastructure give see services, of companies, a when you these an TSMC. do So are And top of to NVIDIA larger built company new see large
cloud emphasize, to want applications the that bloomed things Software-as-a-Service, I years right. compute Amazon other not like manufacture Google built Cloud, So are XX providers. big over of many and the on does have company XX, really that own all Netflix, of $X microchip SaaS trillion NVIDIA, Services top its the last Salesforce, chips, Web Similarly,
your phone Android on app every which iPhone And enabled on you're in. ecosystem ecosystem or depending the OS is by
is It's in companies is other's see enabling, powerful. we innovation rate very you're it's on this building and So this opinion, trillion-dollar very infrastructure. core and tech unbelievable my getting why of -- people each
biotech those okay? works, how This Large own R&D in-house through different infrastructure their and typically of ag, integration engage all to we're way customers industry the about the with vertical all talking is whether manufacturing, have areas or biopharma, not industrial we often industries. from
And in fundamentally around, particular, it digital. my part side, on industry, view, view works ones it so left-hand that that is our zeros the right? the are in a code-based Like the industry is tech moving is and it's all people of reason well
want exactly you have confusion, So a right? -- you is able to someone standards you're to there exactly and wanted. across what very you in to clear get interfaces tell back where what opportunity have Like players
trillion biotech that industry, corn tech whether customers our the industry RNA opinion, be is right? similar structure And across to biotech our biotech going therapy company. is it's I'm in is into could products Well, code-based my gene first our all and hope X we a of DNA And biotechnology, of similar could a or in the that gains. code also my trait $X hopeful perhaps industry, see common human. means that
Okay.
[indiscernible] lot vertically biotech do you robust a into will of biotech up are becoming call, of into canonical our in platform things, if mention end lots even I there can tune since you the technology biotech great, have this drug a industry. is wisdom that investors that company that Now and that always integrating
our research boom like to out, Mark CEO, towards of right? And history creating the great XXXX drug one And I Takeda they genomics Levin, famous we the amazing early at remain here's a acquired of lot if assets, the example, in look it that platform technology. story, A by company. huge really afford is explaining Millennium, and you in being before play can't did for a XXXX, move assets ultimately, from specific Millennium drug leadership, those
own we [indiscernible], say, right? drug infrastructure They'll this find but with compete I potential right. you're the like our hear And you of inevitably, to customers going even from story, your services, us, and did develop
call. I again, is to emphatic here our the So for be people. on X,XXX today Ginkgo potential want customers
in that of $X cash in We bank, have to very cash. the close billion protective
going revenues our from Mark, Our are is rate as cash burn increasing, and new customers you is falling our heard of while up.
So our going developing we end are drugs. to not up own
at in our number scale of platform. and I the infrastructure think service and of revenues and we are built scale we customers terms the uniquely the of the tech on
are sort to business think platform comes biotech. it with going we're now a services of it. category sticking I biased, really infrastructure when we but think to I model I'm make in our own and
for customers, with to we're want so and to that them. intend compete that, And to don't them again, I our sticking know
Okay.
need point to automation, $X a talk why And matters to So which is really R&D, Ginkgo's And infrastructure leaders? in went JPM, into my data more large sets I you generated at our that cost are I investment we right? Why earlier, the modern data component generate this. is the talking to in in but data that close of and reason encourage listen lab about biotech important millions per on points. driving order automation, why because millions to. today this to that is are do R&D you billion right? important all spent And biopharma it we flexible Like biotech? key mentioned in I is of
has And a performance. different data later on about that the number. data This millions And each to see large role asset. And the we library actually DNA that EC assays each public chart sets. set EC here, data top of genomic well is the left you from XXx of for that gives tested we'll brought library their AI of can data, But in genes as on like when classes. number the genes talk of right, on is on an large in-house and hundreds importantly, thousands relative Ginkgo's the an class. points raw And comes we have label that data enormous as different us these it is enzyme to as about of class, the of that
because gray, are company right the This aggregate here is AI now develop in and biotech, call, data important AI to needed assets bottom models salivating give it's in foundation this these down at you us data right. And at an over if right. Ginkgo, watching a
top As principally at assets for the also enable data want but you're we because can really these next a Ginkgo. We think be tool we've going to to on the that they starting are in hear to invested automation section, build developers lot others industry. accumulate on to in of there, resources
to created, really upper the of this most in data most kind want great So point to automation. data more it's just graph, be Ginkgo's of part now But what I the of has I'll assets, got do places. is generate starter have the okay? yet ones, than bigger we But think, biology out, using do we
needing So fine-tuned own without things automated service AI our another customers can develop an by, company that partners model for and their company do example, like lab. to offered
talk I'll next in you'll about in so the that Cradle, hear partnership section. a with about And that our with second
a huge cell can foundation be in business in to the will of to industry. that Scale certain assets may model companies proprietary example, as the interested model they're generate their data build, for want also example. too. some disease This But in that to tech similar line is AI do We an own a
OpenAI of generate use Scale data to of that's into top that right? train ChatGPT. things AI right, happy other the showed It's Tesla at highlight their dog, train paid for large machine help label basically like So AI, the on models, to learning AI analyze absolutely So in at Scale of generating self-driving AI a that's do OpenAI feed business pedestrian customers. chart, to paid a companies, they a models and and data tech lot to company images Scale on I to that cars. scale for Ginkgo a
Okay.
It's of the proprietary can technology both technology one acquisition, was the best of investments scalability automation at we to had our the see flexibility Zymergen's and dramatically the at enhance data generation software within installed made of So a you the bringing automation in things so Ginkgo. site efforts and software because had we supporting we've they they this Zymergen's drop in we're these reconfigurable excited Boston. since call actually one been in. of team then, had RACs, about could we've and what evolved automation And that right so year And cards.
easily so centralized too much, about this big nerding can what's rebuild. in without And without equipment a new exciting out automated needing is a system into we plug to do automation whole new
there's and you you'll idea, the the thing when have great automate, can some clock, to X.X new a automated big you system automation, world have months to a in X of If later. you years lab live ready start
want into you the workflow new system an right have the a then add piece With software, you system, RAC we into top using that the quickly. equipment integrated workflow, automation to if Okay? add equipment, that to can and relatively of
the to generation to now 'XX plan with data keeping manufacture we is And capability, RACs production while more increased ones manufacture Xx this we these 'XX in Ginkgo. only as did that team increased aren't our able We've at importantly, believe flat. hardware important. deploy much we as RACs in we ability And our expensively are them many inexpensively. to fivefold And
and Mike the between give few the Congressman strategic government and Communist Committee Party. to the a competition United talk States AI example, that we the side, experts and committee came right strategy ethical the Just noted on weeks you dominate Chinese Party the Ginkgo, road. Communist the figure on who just can and chaired to Chinese so the set ago, out the Select of to not we rules they House hosted that to Gallagher,
can did look that a that tall see RACs top it showed it really we the for filled a floor to things of is you. talked BiofabX, them building with here about? is last labs a them window is took I units other and these cooling here, week. I facility you And and with out meant but automated over what running about hardware and see So talk actually actually I filled that's huge just with largely to tour we can Well, be needed render, like the to
have to looks data are set feels If This center, you That's what data the doing went the and we're and set is hopefully generating an of certain RAC infrastructure filled this, like data Amazon with like bunch -- across be a to is automation, services the a to very built enable the much of biotech and that and powers of industry. purpose it center going going things a that have infrastructure what hardware to we're right? are except a buildings servers, saw of that here, bunch that.
on right Section All to X.
Okay.
spending Mark way the So biotechnology. want to my have of to technology move services a new excited our cannot work inaugural be its this that do biopharma less companies even industry outsource entire to would the companies of flourish And that labs, infrastructure alone. I'm It's Ideally, that. work just And has to like gets network some like sort at to done the tools really, mainly It we yesterday. could members R&D the see people services buying example service super is going spending and work, chance shift today. percent showed Ginkgo we're that R&D we love and numbers of than that in tech. X%. in We as less right?
People by in R&D I infrastructure total across research XX revenues make want things into R&D services, about of currently total to hundreds going doing outsourced infrastructure. for X% compared announce and to are estimate maybe of our And going on-prem to with research spending and than services reagents hand it to, like as
life this specific were many There's Ginkgo. were integrate customers small the science contract a and our We their Ginkgo. set, day, we're startup a to one invented deeply big large tools Twist when partnered their a is brilliant today. a being give big outside not we culture still at back are technology first largest of the here they that -- in We like companies big for workflow. believers very DNA example, of with and not tech and is To invented
We have M&A bring yesterday transactions the to announced technologies including in-house. we XX years, over also last conducted over X several certain
quick about a excited Diagnostics Biosciences, update we're those Reverie. about Patch And Proof X and why
and RNA and expression. is deploy downstream Patch ML bring to for data to sets, large So ready promoter stability models going and assays in
we so do of a RNA right in And -- lot work have now. we
kind and and exciting quick of very that's So good fit.
companies. nucleases massive offerings nickases Proof offers pharma to overall OMEGA of obligate will libraries that short, and enhance element activity, guided programmable is RNA and code with for mobile our base
So more sort of editing of this technology is sort microbiology in space. the
development. chemistry computational accelerate company that significantly people. a And And our on focused all those about is in drug programs. And data was It's excited are over acquisitions. great in in the then terms up technology to to I capital with allow these of I'm will they're AI to I'm the excited importantly, of awesome Reverie program out areas, AI especially also assets. our this about of coming add accelerate earlier. just real these data leveraging machine human an lastly, It's that acquisition file, Ginkgo speed and build to more big teams build mentioning discovery learning own in And cases,
just several network. can I And highlight are technology of thing benefit suppliers the with our companies XX different But to network. over want partnered that and acquisitions, highlighted, I Okay. is we our now as today our
on And believe of like those for infrastructure biosecurity. I I'll mentioned of just is so sense different the we the be enzymes, earlier, in-house or that you a biotech you give And of in what with outsourced a couple this to AI, manufacturing doing examples doing get companies R&D start of them change, a driving might whether possible. services. pharma, network bring focus cultural All that's to table, something a things
engineering. So is AI the developing of for Cradle, enzyme this DNA area exciting design an models company in
say titer activity of for improve they cell, express to a want in Ginkgo example. customer then to let's titers And the high find it, to an in it So comes they after and enzyme.
that take be end-to-end would a big that Ginkgo little bit. project a So
we'd that be where And so part of integrating give Cradle. you I'll one in
ideal to our go we find a library an of through So and screening first our for designing normal candidate metagenomic customer. steps
right, seed library. big from gene earlier, you So interesting an X.X remember I that that sequence showed billion database we sourced
that then And Now here, works their here's the transferred designs automated at be and where And that we based computationally happy cloned then we're go then could eventually be few customer once the create to Ginkgo's different can leverage DNA sequences project. we BiofabX. Twist candidates designs foundry might leading and and for on Cradle's And generative our AI probably through platform then results, magic, synthesized and tested a those would labs how Ginkgo the loop given a library seed times in protein with a respective using or to sequence. customer. of
Ginkgo side, a to And really able infrastructure different providers, who's AI couple synthesis drive DNA of lab in that and Twist the importantly, we've together providing computational someone okay? been case, magic, pull horsepower at of a lot
we're to to And work at the browser, from be really comfort do say. so can the also Cradle's their Cradle lab likes able of we customers And proteins them for engineer Ginkgo. excited as help to
really this to want I say, love vision. I
I R&D hats, pipe Ph.D. about a have a I did to X biology, your infrastructure hat. -- designing, experiments I spent these a products. put try will holding like so what services, understanding next biotech want and But they drug to scientists, years they're developing outsourced right? spend know reading workflows, the development attack of scientists, and Okay, in they time so pipe model their down because
moving outsourced time all have right? lab experimental your use of work. services, their that biology. all spend And from is around bench, world the a folks who experience the all It of the of manually comfort lab this love that browser, just of liquids design in not vision best in both and the Cradle's Not I doing
Okay.
an bit.bio. I'd is sort like So of case with study illustrative partner to another highlight
terrific disease iPSC effectively for cell ioCells, example, designs they across to our type behaviors. optimized multitude a human needed be has and call may in created customer a incorporate at The screen better looking the lines which libraries these our and bit.bio's study what cell state, and can also bit.bio modalities and customize acquisition. can that particular asset and are predict So test of models heard, a drug to vivo you in cells, we promoters for differentiated of like lines drug we large a Patch programs, different wild are into gene to editors, which are disease various represent
of right? it them, [indiscernible] channel licensing with technologies is lines customers. paying so throughput, for cell companies easier high like Ginkgo and here distribution could but The for their great some cell lines, they in and to theirs. integrate could you gets is Ginkgo latest So in I like more it key, companies both And for new lines, need our cell those magic make a running those at easier bit.bio be at gets bit.bio right? that we strains exist have to which and the needs biopharma to to So companies right? also bit.bio, bit.bio sell access
team And and growing. mentioned, a as I XX-person Ginkgo has commercial
hands going companies a show So being the the large assets multitude And it increase infrastructure biopharma of X% we're together number space going these spending to up out hopefully, that helps hopeful Ginkgo services that is customers. by the to or to research go get make that whatever X% and whole able to of their in coming of also technology programs. technologies in these in R&D to the for tool It industry. out real
really I'll us success they an reducing scientists biopharma tell development. time work Large AI models big care it's drug And can customers, customers data end reducing in probability like extra in the hands about we here. this, of increase sets success, costs. in R&D and think, the is So of point what the our of at and the to results repeatedly increase odds with
There's AI, not of or and belief about is our noise like replacing lot robot scientists That automation, at scientists whatever. Ginkgo.
services We the industry. to take trying scientists model the are the out loop infrastructure of with for not
let using that at they not design comes paper it's scientists enormous like that next all then decide scientists. So This to much data the some like them can and about give is design, scale handle able out not models the robotic of It powering larger automation to that right? insight by super to back Combi-Camp. of them experiments on is to be experiments your so round biological
software capability there. software and is It's still years If last developing The years the difference tech, is Stark like developer they're XX it ago It is the product still development or -- products, developer developer gosh, software of today, the in again, software -- think developer my unbelievable, they're today, tools the oh in Tony XX in a over there. change were a something. right? you and
as much mature. completing more not sciences. we're there's scale for grew more engineering year what now fact, every better various Because build speed to development software jobs, you do talking here. In with talk product tools. market faster, removing see programs about and software we We're want about bigger right? the approaches really so talking Ginkgo about as get We That's at
think serially moving approaches on many a one to seeing result rather you parallel. small increase hand than the be can traditional try is will can of than then infrastructure approach next of by as how work and experiments, parallel many speed experiments your in try batch services can reason one And the better to you you scale of in on guessing of
cost. Finally,
Another in success myth R&D, want care just costs I doesn't time biopharma hear a lot they of more whatever. or about
in have head, seeing their And average building of basically have have talked then we do, as -- we we lot think company. you cost If And genetic scaled to a in that at will designs. a research drop about the you are out campaigns. an the find is designing, at they XX% testing a to fact, cycle R&D of our the and Ginkgo, budgets campaign XX% year-over-year
R&D for if if year how research growing doesn't. And we just be I in every change an scale they that's is industry by But done. think does to It tech. and lab the we really services the scale. keep to want as does cheaper automation important going did engine The hand, work fact is getting matter our will at not cheaper with with in-house keep of the bench get infrastructure
All right.
Finally, a engineering. strategic our how biosecurity last to infrastructure as for day, the integrator our want systems cell in Ginkgo's global is alongside in cover which I topic work about leading
want so often mode. a but tend of shown I the a or in how less We I've biothreat they information Now they effort and ton than because in flying effective global but to reiterate to it this could in response put is data. we're measures important reactive to you past, globally, plug be slower into gathering in blind be slide gaps
how like the approach was way biosecurity letting we roughly you approached give I coming would to we get to head, hurricane And be tracking, a know hit everybody not hospitals. Florida, effective. We was Florida, had coast it track Brooklyn, hurricane okay? infectious disease the the until my that where do. today, all wait it right, equivalent And this be in like way at Like once what of would do that we And that is we
we shot should hurricane The are the infectious husbandry hospitals monitoring to has People they in mass, of get baseline Again, all places vision. airports, at disease arrive at hit monitoring where genetic look the disease, a right? starting a picture. to like when satellites most at okay? the in sick lot infectious at That's things for data people in get animal cheaply time. Instead, can one facilities, we congregate, shore, be anywhere
this boost in really and we our months made And that our surrounding X within the data and space intelligence major capabilities. in few past last announcements partnerships the days, will
with scale scale services. surveillance Illumina tools aim increase leverage example, for new Illumina us more of together, call to sequencing leading scope allow rapidly is these will the Our globally. end-to-end. countries. We pathogen Ginkgo's agreement pathogen partnership to to is monitoring programs genomic my next-gen and we And and bioradar, The
with are that's what empower, about want other they genetic like of variance things I have like spreading And sequence in more the countries so local we and monitoring, diseases as the to So COVID different globe, visibility capacity. around in next. words, particular in talk we
partnership launching it we CUBE-D Doha, and center in and Zone. hub we for CUBE-D complete, Excellence network. Free serving bioradar Center Capital call when key be Qatar expect Just Ginkgo's a in with first in Unified both we major programs as Doha across this that week, Biosecurity to the Qatar in announced we'll And Venture support the the region, broader -- global the for
and piece advance intelligence important. of And globally. infrastructure development the monitoring CUBE-D the support foundational to next-generation a pathogen of Biosecurity development and will very biological enabled biosecurity Biosecurity That's of be also analytics, leaders
in to is excited the gratified ecosystems. complement with program CDC see airports here in U.S. We're to the into international here a [indiscernible] and in work regional the we Doha. leaning of what partners our It biosecurity long-term U.S. that's great doing growth the similar do we're to
to new the global for to going growing resilience market demonstrate for the in momentum rapid is biosecurity biological progress building and the And initiatives These threats. and huge be important. this potential
in kids why to your school business complementary. want of And parts build out so X we happen you need If Ginkgo's are high flowers, biosecurity. that's also safely. designing that want these We world to
the accomplished about far, really excited the shop be to expand continue the of that in of one-stop types infrastructure for work Ginkgo summary, in services. to to couldn't okay, done a business. excited I'm be and was to biotech our growth great we've all offerings thus work and especially the year we enable in So come already we've what for as more 'XX I XXXX done
All right.
it I'll to for Now back Q&A. hand Megan
